Corbus pharmaceuticals holdings, inc. (CRBP)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Revenue from awards

36,019

36,143

34,660

32,924

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue from awards

-

-

-

-

-

-

-

-

2,096

2,440

2,815

2,762

2,808

1,911

1,900

1,327

1,044

648

0

0

0

-

0

-

-

-

Operating expenses:
Research and development

91,768

89,604

81,898

72,553

60,632

48,613

41,119

33,934

29,438

26,038

23,132

21,825

19,628

15,436

11,879

9,198

7,339

5,888

4,637

3,454

1,917

1,255

712

0

0

0

General and administrative

24,718

23,643

21,104

18,751

16,530

12,956

11,793

10,743

9,633

8,964

8,956

8,586

7,729

6,459

4,933

3,963

3,911

3,613

3,258

2,834

2,159

1,391

720

0

0

0

Total operating expenses

116,487

113,248

103,002

91,304

77,163

61,569

52,913

44,677

39,072

35,003

32,089

30,412

27,358

21,896

16,813

13,162

11,250

9,502

7,896

6,288

4,076

2,647

1,433

0

0

0

Operating loss

-80,467

-77,104

-67,505

-57,306

-71,405

-56,747

-50,018

-42,077

-36,975

-32,562

-29,273

-27,650

-24,550

-19,985

-14,913

-11,834

-10,205

-8,853

-7,611

-6,175

-4,076

-2,647

-1,433

0

0

0

Other income (expense):
Other income

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income, net

-

-

1,320

1,296

-

-

871

646

385

183

50

8

7

0

1

-0

0

-

0

0

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

24

32

0

0

0

Interest income, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

2

1

0

0

0

Forgiveness of interest on note payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

Gain on the settlement of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28

0

0

0

-

Foreign currency exchange gain (loss), net

14

-158

-104

20

80

92

87

7

-61

-41

-74

-37

-28

-14

-16

-1

0

-

0

0

-

4

0

0

0

0

Other income, net

5,591

5,650

5,326

1,316

1,193

1,075

959

653

323

141

-24

-29

-21

-13

-13

0

-1

2

-0

157

116

106

93

0

0

0

Net loss

-74,875

-71,453

-62,179

-55,989

-70,211

-55,672

-49,059

-41,424

-36,651

-32,421

-29,298

-27,679

-24,571

-19,998

-14,926

-11,834

-10,207

-8,850

-7,612

-6,018

-3,960

-2,540

-1,339

0

0

0

Net income (loss) per share, basic

-

-

-

0.03

-

-

-

-0.21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share, diluted

-

-

-

0.03

-

-

-

-0.21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares outstanding, basic

-

-

-

64,546

-

-

-

57,157

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares outstanding, diluted

-

-

-

68,511

-

-

-

57,157

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basic and diluted

-0.43

-

-0.32

-

-0.43

-

-0.26

-

-0.21

-0.20

-0.14

-0.15

-0.16

-0.17

-0.12

-0.11

-0.08

-0.06

-0.06

-0.10

-0.06

-0.06

-0.03

-0.02

-0.02

-0.01

Weighted average number of common shares outstanding, basic and diluted

69,272

-

64,660

-

61,675

-

57,218

-

56,367

53,828

50,221

50,193

46,381

44,348

43,783

38,748

37,605

37,857

34,770

26,901

25,871

26,060

25,542

22,071

6,964

6,964